Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

UPDATE 3-AstraZeneca resumes UK trials of COVID-19 vaccine halted by patient illness

Sat, 12th Sep 2020 14:51

(Adds India's Serum Institute, reaction)

By Michael Holden

LONDON, Sept 12 (Reuters) - AstraZeneca has resumed
British clinical trials of its COVID-19 vaccine, one of the most
advanced in development, after getting the green light from
safety watchdogs, the company said on Saturday.

The late-stage trials of the experimental vaccine, developed
with researchers from the University of Oxford, were suspended
this week after an illness in a study subject in Britain,
casting doubts on an early rollout.

"On 6 September, the standard review process triggered a
voluntary pause to vaccination across all global trials to allow
review of safety data by independent committees, and
international regulators," AstraZeneca said.

It added that safety reviewers had recommended to Britain's
Medicines Health Regulatory Authority (MHRA) that it was safe to
resume the British trials.

The patient involved in the study had been reportedly
suffering from neurological symptoms associated with a rare
spinal inflammatory disorder called transverse myelitis.

AstraZeneca, based in Cambridge, said it could not disclose
further medical information.

"The Company will continue to work with health authorities
across the world and be guided as to when other clinical trials
can resume to provide the vaccine broadly, equitably and at no
profit during this pandemic," AstraZeneca said.

It declined to elaborate further on when other global trials
were expected to restart, but the Serum Institute of India said
it would restart its trials once it had permission from the
Drugs Controller General of India.

Governments around the world are desperate for a vaccine to
help end the pandemic, which has caused more than 900,000 deaths
and global economic turmoil. The World Health Organization (WHO)
had flagged AstraZeneca's as the most promising.

The vaccine is in late-stage clinical trials in the United
States, Britain, Brazil and South Africa and additional trials
are planned in Japan and Russia.

The pause of the trials came after reports that the United
States was aiming for fast-track authorization or approval of a
vaccine before November's presidential election.

Leading U.S. and European vaccine developers have pledged to
uphold scientific safety and efficacy standards for their
experimental vaccines and not bow to political pressures to rush
the process.

AstraZeneca has already agreed to supply close to three
billion doses to governments across the globe - more than any
other vaccine project.

The WHO's chief scientist said the pause in the trial should
serve as a "wake-up" call that there would be ups and downs in
the development of a vaccine.

"Inevitably with such a large trial there will be times when
safety issues arise," said Peter Openshaw, professor of
experimental medicine at Imperial College London.

"We must all hope that there are no future events and that
the vaccine proves both safe and effective."
(Reporting by Michael Holden; Additional reporting by Radhika
Anilkumar in Bengaluru, Editing by William Maclean and Pravin
Char)

Related Shares

More News

Tuesday broker round-up

(Sharecast News) - BP: Barclays upgrades to top pick with a target price of 475p.

18 May 21 14:00

Oxford Biomedica jumps after AstraZeneca orders more Covid-19 vaccines

Oxford Biomedica jumps after AstraZeneca orders more Covid-19 vaccines

18 May 21 11:52

Oxford Biomedica ups revenue forecast as AstraZeneca lifts vaccine output

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.

18 May 21 08:13

LONDON MARKET PRE-OPEN: Phoenix Group confirms talks for European sale

LONDON MARKET PRE-OPEN: Phoenix Group confirms talks for European sale

18 May 21 07:47

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.